Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Status:
Active, not recruiting

Trial end date:
2022-12-22

Target enrollment:

Participant gender:

This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.

Phase 2

Novartis Pharmaceuticals